In our study, 5/29 patients (17%) developed severe pneumopathy (inflammatory or infectious) during treatment, more than in the results of a meta-analysis with patients treated by mTOR inhibitors, in which the incidence of high grades pneumonitis (grades 3 and 4) was 2.4%.[21] The radiologic presentation in computed tomography was typically diffuse nonspecific alveolar-interstitial pneumonitis (Fig. 3). The gene discussed is MTOR; the disease is pneumonitis.